Medical
What Makes a Healthcare-Ready Cannabinoid Ingredient?
For much of the cannabinoid supply market, the model has been simple: make the molecule, test the batch, sell the material. If the product meets basic specifications, passes third-party testing, and can be produced at a competitive price, it is considered ready for market. That model has supported much of the consumer cannabinoid industry, where […]
Cannabis Biopharma Company Enters Fight Over CMS Hemp Pilot
A cannabis biopharma company is seeking to join the federal lawsuit challenging the Centers for Medicare & Medicaid Services’ (CMS) new hemp and CBD pilot program, adding a pharmaceutical voice to a government-sanctioned program allowing untested and unregulated hemp products into the marketplace. MMJ International Holdings and its subsidiaries, MMJ BioPharma Labs and MMJ BioPharma […]
Are Acidic Cannabinoids the Next Frontier for Product Innovation?
While the cannabis industry has made significant strides in incorporating minor cannabinoids into product formulations, a vast number of therapeutic compounds remain largely unexplored. Researchers and cannabis physicians have been experimenting with acidic cannabinoids for several years with promising results, but the broader industry is only now beginning to catch up. As extraction technologies improve […]
The Power of AI and How it Will Transform Cannabis Medicine
Biotechnology, cannabis medicine, and the rapid advancements in artificial intelligence (AI) and machine learning (ML) are beginning to converge. Hemant Kumar Bid, program director for the Master of Science in Biotechnology and the Medical Cannabis concentration at Morehouse School of Medicine, believes this convergence could dramatically accelerate the development of cannabis-based therapies. With AI, cannabis […]
Building Inside Maryland’s Limited License Cannabis Market
Maryland launched its medical cannabis program in 2018 and transitioned to adult use in 2024 as a limited-license state. Currently, there are 108 active dispensaries, with additional operators expected to come online following a March 2024 lottery that awarded conditional licenses to social equity entrepreneurs. However, these licensees still need to clear a vetting process […]
NIH Releases Scientific Paper on the Therapeutic Value of Acidic Cannabinoids
A new scientific review published in the National Library of Medicine (NIH) shines a spotlight on one of the most overlooked areas of cannabis science: the untapped benefits of acidic cannabinoids naturally produced by Cannabis sativa — THCA, CBDA, CBGA, and CBCA. These compounds are the biosynthetic precursors to THC, CBD, CBG, and CBC. But […]
The Latest CBD Scientific Research From Western Washington University
Josh Kaplan, PhD, is a neuroscientist and associate professor in the Behavioral Neuroscience program at Western Washington University, where his lab focuses on optimizing cannabidiol (CBD) based medicines for pediatric conditions. His work examines not only CBD’s therapeutic potential, but also its long-term developmental effects on the brain, an area of growing importance as cannabinoid […]
The Case For Cannabis Telemedicine: Can it Work in the US?
It has been one year since Germany fully legalized cannabis on April 1, 2024, following the launch of its medical program in 2017. While cannabis was removed from the narcotics list, Germany continues to take a medical-first approach. Few expect full adult-use legalization anytime soon, particularly after a conservative government was elected last year. According […]
Platform Launches Insurance Coverage for Medical Cannabis
A Cleveland-based health-tech company, EM2P2, has launched a platform that could change how Americans pay for medical cannabis. Its new product, CannaLnx, claims to make cannabis care reimbursable, compliant, and accessible by finally allowing patients to apply health-benefit dollars toward cannabis purchases in legal states. Developed as the exclusive tech partner of the American Council […]
The Fight For Cannabis and Cancer Research
For decades, cannabis has lived in a research dead zone. Federal prohibition has blocked meaningful grants, limited clinical trials, and left millions of people with cancer relying on anecdotal evidence for treatment rather than data. As founders of E.R.I.C. Cancer Playbook, we refused to accept that. If institutions didn’t collect the data, patients and the […]